Featured Story

  • Unvaccinated clusters bear brunt of bad year for measles in U.S.

    On the surface, measles looks like a success story for the U.S. childhood immunization program, with vaccination rates topping targets in each of the past 5 years. Yet 2013 has seen a spate of measles outbreaks, resulting in one of the worst years since the U.S. declared it had eliminated the disease in 2000.

Study links delayed vaccines to increased risk of whooping cough

While there is no evidence to suggest alternative immunization schedules cut the risk of adverse events, a JAMA paper shows they do increase the likelihood of contracting disease.

India gives 114 kids the wrong vaccine in polio mix-up

Vaccines have faced heavy scrutiny in India in recent months, with the safety of pentavalent jabs and ethics of a PATH project being questioned.

Brain cancer vaccine data gives Agenus' stock a boost

Agenus has had a topsy-turvy month. Its share price fell off a cliff after the GlaxoSmithKline vaccine that uses its adjuvant failed a Phase III trial, only to rally this week on the back of news about its own clinical candidate.

Visterra advances universal flu antibody to cusp of Phase I

Massachusetts-based biotech Visterra is preparing to move its universal influenza therapy into the clinic.

Pfizer details plans to expand vaccine portfolio beyond Prevnar

Pfizer is an unusual player in the vaccine space. It is the fourth biggest vaccine company by revenue, yet almost wholly reliant on one product--Prevnar 13. At a media event in New York this week, the company's top brass explained how they plan to build out the business in the coming years.


From Our Sister Sites

FierceMarkets Network
  • FierceBiotech
  • FierceBiotechIT
  • FierceBiotechResearch
  • FierceBiomarkers
  • FierceDrugDelivery
  • FierceMedicalDevices
  • FierceVaccines
  • FiercePharma
  • FiercePharmaManufacturing
  • FierceCRO
  • FierceDiagnostics
  • More Fierce Network sites
Dx maker Veracyte files planned $75M IPO

Veracyte, a molecular diagnostics company, filed plans to raise nearly $75 million in a proposed IPO, becoming the latest life sciences operation this year to eye public company waters.

Bind collects $70.5M IPO to support Accurin tech

Bind Therapeutics, currently developing a nanotech delivery platform for cancer, raised $70.5 million in a public offering of 4,700,00 shares at $15 each. The company began trading Friday under the ticker symbol "BIND."